Last reviewed · How we verify
Caffeine citrate oral solution
Caffeine citrate oral solution is a Adenosine receptor antagonist; methylxanthine Small molecule drug developed by NICHD Global Network for Women's and Children's Health. It is currently FDA-approved for Apnea of prematurity in preterm infants, Neonatal respiratory depression. Also known as: Caffeine, CafCit, Caffeine Ingestion, YA Kofeiinitabletti 100 mg, Yliopiston apteekki.
Caffeine citrate is a nonselective adenosine receptor antagonist that blocks adenosine-mediated central nervous system depression, promoting wakefulness and respiratory stimulation.
Caffeine citrate is a nonselective adenosine receptor antagonist that blocks adenosine-mediated central nervous system depression, promoting wakefulness and respiratory stimulation. Used for Apnea of prematurity in preterm infants, Neonatal respiratory depression.
At a glance
| Generic name | Caffeine citrate oral solution |
|---|---|
| Also known as | Caffeine, CafCit, Caffeine Ingestion, YA Kofeiinitabletti 100 mg, Yliopiston apteekki, 200 mg Vivarin Tablet |
| Sponsor | NICHD Global Network for Women's and Children's Health |
| Drug class | Adenosine receptor antagonist; methylxanthine |
| Target | Adenosine receptors (A1, A2A) |
| Modality | Small molecule |
| Therapeutic area | Neonatology; Respiratory |
| Phase | FDA-approved |
Mechanism of action
Caffeine competitively inhibits adenosine receptors (A1 and A2A) in the brain and spinal cord, preventing adenosine's inhibitory effects on neuronal activity. This leads to increased alertness, improved respiratory drive, and enhanced metabolic activity. In neonates, it is primarily used to stimulate respiration and reduce apnea episodes by increasing central nervous system excitability.
Approved indications
- Apnea of prematurity in preterm infants
- Neonatal respiratory depression
Common side effects
- Tachycardia
- Jitteriness
- Irritability
- Feeding intolerance
- Necrotizing enterocolitis (rare)
Key clinical trials
- To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers (PHASE1)
- Caffeine for Hypoxic Ischemic Encephalopathy (PHASE3)
- CaffeinICU Study - A Study on Oral Caffeine in ICU Patients With Coma (PHASE2)
- Study of the Neurophysiological Response to Foodstuffs (NA)
- Effect of Caffeine on Heart Rate Variability in Newborns (NA)
- Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study (PHASE1)
- Caffeine to Reduce Mechanical Ventilation in Preterm Infants (NA)
- Sorting of Oral Sensations
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caffeine citrate oral solution CI brief — competitive landscape report
- Caffeine citrate oral solution updates RSS · CI watch RSS
- NICHD Global Network for Women's and Children's Health portfolio CI
Frequently asked questions about Caffeine citrate oral solution
What is Caffeine citrate oral solution?
How does Caffeine citrate oral solution work?
What is Caffeine citrate oral solution used for?
Who makes Caffeine citrate oral solution?
Is Caffeine citrate oral solution also known as anything else?
What drug class is Caffeine citrate oral solution in?
What development phase is Caffeine citrate oral solution in?
What are the side effects of Caffeine citrate oral solution?
What does Caffeine citrate oral solution target?
Related
- Drug class: All Adenosine receptor antagonist; methylxanthine drugs
- Target: All drugs targeting Adenosine receptors (A1, A2A)
- Manufacturer: NICHD Global Network for Women's and Children's Health — full pipeline
- Therapeutic area: All drugs in Neonatology; Respiratory
- Indication: Drugs for Apnea of prematurity in preterm infants
- Indication: Drugs for Neonatal respiratory depression
- Also known as: Caffeine, CafCit, Caffeine Ingestion, YA Kofeiinitabletti 100 mg, Yliopiston apteekki, 200 mg Vivarin Tablet
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing